Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program.

被引：5

作者：

Itzykson, Raphael ^{[1
]}

Thepot, Sylvain ^{[1
]}

Recher, Christian ^{[2
]}

Delaunay, Jacques ^{[3
]}

Quesnel, Bruno ^{[4
]}

Dreyfus, Francois ^{[5
]}

Koka, Anne Marfaing ^{[6
]}

Vey, Norbert ^{[7
]}

Stamatoullas, Aspasia ^{[8
]}

Gyan, Emmanuel ^{[9
]}

Cluzeau, Thomas ^{[10
]}

Rousselot, Philippe ^{[11
]}

Reman, Oumedaly ^{[12
]}

Plantier, Isabelle ^{[13
]}

Marolleau, Jean Pierre ^{[14
]}

More, Pierre ^{[15
]}

Wattel, Eric ^{[16
]}

Visanica, Sorin ^{[17
]}

Zerhouni, Chahinez ^{[1
]}

Bordessoule, Dominique ^{[18
]}

Ades, Lionel

Fenaux, Pierre ^{[19
,20
]}

Gardin, Claude

机构：

[1] GFM, Bobigny, France

[2] CHU Purpan, Toulouse, France

[3] CHU Nantes, F-44035 Nantes 01, France

[4] CHRU, Lille, France

[5] Hop Cochin, AP HP, F-75674 Paris, France

[6] Hop Antoine Beclere, AP HP, Clamart, France

[7] Inst J Paoli I Calmettes, F-13009 Marseille, France

[8] Ctr Henri Becquerel, F-76038 Rouen, France

[9] CHU Tours, Tours, France

[10] CHU, Nice, France

[11] CH, Versailles, France

[12] CHU Caen, F-14000 Caen, France

[13] CH, Roubaix, France

[14] CHU, Amiens, France

[15] CH, Lens, France

[16] Hop Edouard Herriot, Lyon, France

[17] CHR, Metz, France

[18] CHU, Limoges, France

[19] Univ Paris 13, Hop Avicenne, AP HP, Bobigny, France

[20] Inst Gustave Roussy, INSERM 848, Bobigny, France

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

10.1182/blood.V114.22.843.843

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：436 / 436

页数：1

共 50 条

[31] Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study
Abedin, Sameem
Murthy, Guru Subramanian Guru
Runaas, Lyndsey
Michaelis, Laura C.
Atallah, Ehab L.
Hamadani, Mehdi
Harrington, Alexandra M.
Carlson, Karen
BLOOD, 2019, 134
[32] Allogeneic hematopoietic cell transplantation in aplasia after Cladribine/Cytarabine salvage chemotherapy for refractory or relapsed AML and MDS - a single center experience
Vydra, Jan
Markova, Marketa St'astna
Valkova, Veronika
Novakova, Ludmila
Cemusova, Barbora
Soukup, Petr
Kolar, Michal
Vitek, Antonin
Cetkovsky, Petr
BONE MARROW TRANSPLANTATION, 2018, 53 : 147 - 148
[33] Sequential salvage chemotherapy and lintuzumab-Ac225 results in deep responses and prolonged survival in adverse risk relapsed/refractory AML and in AML patients that received prior venetoclax therapy
Abedin, Sameem M.
Murthy, Guru Subramanian Guru
Desai, Avinash
Chen, Mary
Atallah, Ehab L.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[34] Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study
Usui, Noriko
Takeshita, Akihiro
Nakaseko, Chiaki
Dobashi, Nobuaki
Fujita, Hiroyuki
Kiyoi, Hitoshi
Kobayashi, Yukio
Sakura, Toru
Yahagi, Yuichi
Shigeno, Kazuyuki
Ohwada, Chikako
Miyazaki, Yasushi
Ohtake, Shigeki
Miyawaki, Shuichi
Naoe, Tomoki
Ohnishi, Kazunori
CANCER SCIENCE, 2011, 102 (07) : 1358 - 1365
[35] Treatment Patterns Among Patients with Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia after Intensive Induction Chemotherapy
Rojek, Alexandra E.
McCormick, Benjamin J.
Cwykiel, Joanna
Odetola, Oluwatobi
Abaza, Yasmin
Achar, Rohan
Shallis, Rory M.
Bradshaw, Danielle
Standridge, Meaghan
Kota, Vamsi K.
Badar, Talha
Patel, Anand Ashwin
BLOOD, 2023, 142
[36] Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma.: Results of a single-centre study of 65 patients
Soussain, C
Souleau, B
Gabarre, J
Zouabi, H
Sutton, L
Boccaccio, C
Albin, N
Charlotte, F
Merle-Béral, H
Delort, J
Binet, JL
Leblond, V
LEUKEMIA & LYMPHOMA, 1999, 33 (5-6) : 543 - 550
[37] Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results
Klisovic, Rebecca B.
Wang, Hongyan
Walker, Alison
Walsh, Katherine
Vasu, Sumithira
Garzon, Ramiro
Devine, Steven M.
Wang, Jiang
Garr, Celia
Norris, Adam
Byrd, John C.
Grever, Michael R.
Blum, William
Chan, Kenneth K.
Marcucci, Guido
BLOOD, 2012, 120 (21)
[38] Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy
Thomas, X
Le, QH
De Botton, S
Raffoux, E
Chelghoum, Y
Pautas, C
Dreyfus, F
Dhedin, N
Vekhoff, A
Troncy, J
Pigneux, A
De Revel, T
Reman, O
Travade, P
Thiebaut, A
Guerci, A
Elhamri, M
Fenaux, P
Dombret, H
Michallet, M
LEUKEMIA & LYMPHOMA, 2005, 46 (07) : 1007 - 1016
[39] Depression and expectations for cure in older adults with advanced myelodysplastic syndrome (aMDS) or acute myeloid leukemia (AML) receiving intensive chemotherapy (IC) and non-intensive chemotherapy (NIC): Early results from a prospective study.
Sekeres, MA
Stone, RM
Zahrieh, D
Neuberg, D
Weeks, JC
Lee, SJ
BLOOD, 2001, 98 (11) : 625A - 625A
[40] Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
Malard, Florent
Bobin, Arthur
Labopin, Myriam
Karlin, Lionel
Frenzel, Laurent
Roussel, Murielle
Vignon, Marguerite
Godet, Sophie
Chalopin, Thomas
Moyer, Perrine
Chalayer, Emilie
Piocelle, Frederique Orsini
Mariette, Clara
Croizier, Carolyne
Sohn, Claudine
Dib, Mamoun
Le Calloch, Ronan
Ali-Ammar, Nadia
Loirat, Marion
Benbrahim, Omar
Payssot, Alexandre
Trebouet, Adrien
Perrot, Aurore
Leleu, Xavier
Mohty, Mohamad
BLOOD CANCER JOURNAL, 2024, 14 (01):

← 1 2 3 4 5 →